7 Tales from 20 years of Deep Tech Life Science Venture Capital Investment
Sebastien Groyer - A Venture Capitalist turned Serial Entrepreneur
In 16 years of supporting life science companies in raising capital and structuring deals with the pharma industry, I never felt that venture capital exists in abundance on the European market.
It always looked to me that the market is very VC-friendly on the European stage - plenty of teams and technology meet with a scarcity of available funds.
This was the reason to start the LSG2G Lunch MeetUps in June 2017. I remember our first meetup with 15 Life Science Enthusiasts like Pharma Business Developer, Life Science Investors, Life Science Entrepreneurs, and Service Partners. We discussed the state of Investments in Biotech in Europe.
Availability of Venture Capital in Europe
According to Dealroom.co 2017, the transaction volume in life science companies in 2017 was about 3,7 billion euros.
In 2020 investments increased to 6 billion Euros, which was already achieved by July this year. It looks promising to see investments double in the last four years since we started the LSG2G initiative.
Sebastien Groyer - 20 Years Experience in Life Science Venture Investments
So far, to the analytics of Venture Investments in Biotech in Europe. Numbers are fine but leave a few important questions open.
Who are the people behind those numbers?
What stories did they write in their career?
What lessons did they learn in the world of VC Investments?
Business is always done between people, and I believe sharing stories helps to understand how an industry works and how deep tech can be transformed into products that help the patients.
I am delighted to welcome to this episode Sebastien Groyer who brings 20 years of profound investment expertise to the conversation table. In this episode, he will share
7 Tales from 20 Years of Deep Tech Life Science Investments
and also will tell why he turned into a serial entrepreneur in 2021.
Join us for this great conversation and register today:
Global venture capital is crushing all records in 2021. Global VC investment has reached an all-time high in 2021 having already smashed last year’s records with 2.3x year-on-year growth. Since the start of the year to date, more than €264B has been invested globally – up from €114B for the same period in 2020. Read more…
The Origin and Evolution of the Startup Studio The fascinating origin and evolution of the startup studio, aka venture studio model, that has truly gone global. (First published 2018, revised 2021). Read more…
In data: Europe’s largest funding rounds of 2021 Most European countries have doubled –– and some tripled –– their startup investment. So which European startups brought big money home? Read more…
It was great fun to talk with Walter Stockinger, Co-Founder of Hadean Ventures, about the topic of Life Science Investments.
We covered the following questions:
How do Venture Funds operate?
What do you need to know about approaching VCs?
What is the purpose of a VC?
Why are exits necessary for VCs?
And what exit strategies are relevant?
Why do VCs raise money, and from whom?
Use the opportunity to get your answer directly from a VC.
These companies make the community, this newsletter, and the LSG2G Podcast possible, so go check them out and thank them for their support!
You are receiving the LSG2G-Letter because you either signed up or attended one of the events organized by LSG2G. Feel free to unsubscribe if you aren’t finding this valuable.
Nothing in this email is intended to serve as financial advice. Do your own research.